In patients who do not achieve biochemical control of the disease [7] but have documented partial response to SRLs (>50 % reduction of GH and IGF-1 vs. baseline and/or tumor shrinkage >20 %) either switching to Pegvisomant monotherapy or combination therapy Pegvisomant + SRL should be considered (DR). This evidence concerns the gene IGF1 and neoplasm.